3.86
price down icon4.93%   -0.20
after-market Handel nachbörslich: 3.89 0.03 +0.78%
loading
Schlusskurs vom Vortag:
$4.06
Offen:
$3.93
24-Stunden-Volumen:
411.48K
Relative Volume:
3.85
Marktkapitalisierung:
$32.49M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.0394
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
-11.26%
1M Leistung:
-46.76%
6M Leistung:
-70.79%
1J Leistung:
-79.97%
1-Tages-Spanne:
Value
$3.71
$3.9944
1-Wochen-Bereich:
Value
$3.51
$4.64
52-Wochen-Spanne:
Value
$3.51
$21.60

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Firmenname
Karyopharm Therapeutics Inc
Name
Telefon
617-658-0600
Name
Adresse
85 WELLS AVENUE, NEWTON, MA
Name
Mitarbeiter
0
Name
Twitter
@Karyopharm
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
KPTI's Discussions on Twitter

Vergleichen Sie KPTI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
3.86 32.49M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-19 Eingeleitet Piper Sandler Overweight
2022-11-04 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-09 Hochstufung JP Morgan Underweight → Neutral
2021-11-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-08-06 Herabstufung JP Morgan Overweight → Neutral
2021-08-06 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-08-06 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-07-02 Eingeleitet Morgan Stanley Overweight
2020-03-04 Eingeleitet Barclays Overweight
2020-01-17 Herabstufung Wedbush Outperform → Neutral
2019-07-23 Hochstufung JP Morgan Neutral → Overweight
2019-07-05 Bestätigt H.C. Wainwright Buy
2019-07-05 Bestätigt Robert W. Baird Outperform
2019-03-01 Herabstufung JP Morgan Overweight → Neutral
2019-02-28 Bestätigt BofA/Merrill Underperform
2019-02-27 Herabstufung BofA/Merrill Neutral → Underperform
2019-01-03 Hochstufung BofA/Merrill Underperform → Neutral
2018-12-03 Eingeleitet B. Riley FBR Buy
2018-11-09 Hochstufung Wedbush Neutral → Outperform
2018-05-24 Herabstufung Wedbush Outperform → Neutral
2018-04-02 Fortgesetzt Leerink Partners Outperform
2017-11-15 Fortgesetzt H.C. Wainwright Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2016-09-08 Bestätigt H.C. Wainwright Buy
2016-08-30 Hochstufung Jefferies Hold → Buy
2016-08-18 Eingeleitet H.C. Wainwright Buy
2016-06-28 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

pulisher
Apr 02, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Apr 01, 2025
pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm Therapeutics Executives Sell Shares - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM

Mar 03, 2025
pulisher
Mar 03, 2025

KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com

Mar 03, 2025
pulisher
Mar 02, 2025

Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat

Mar 02, 2025
pulisher
Mar 01, 2025

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.

Mar 01, 2025
pulisher
Mar 01, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 25, 2025

Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Research Analysts Offer Predictions for KPTI Q1 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 23, 2025

What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings? - The AM Reporter

Feb 23, 2025
pulisher
Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025
pulisher
Feb 21, 2025

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025

Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):